Effects of levocarnitine on cardiac function, urinary albumin, hs-CRP, BNP, and troponin in patients with coronary heart disease and heart failure

Finegold, 2013, Mortality from ischaemic heart disease by country, region, and age: Statistics from World Health Organisation and United Nations, Int J Cardiol, 168, 934, 10.1016/j.ijcard.2012.10.046 Moran, 2014, Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study, Circulation, 129, 1483, 10.1161/CIRCULATIONAHA.113.004042 Nicholas, 2014, Corrigendum to: Cardiovascular disease in Europe 2014: epidemiological update, Eur Heart J, 35, 2950, 10.1093/eurheartj/ehu299 Sharma, 2015, Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure, Am J Cardiol, 115, 1428, 10.1016/j.amjcard.2015.02.024 O'Neal, 2017, Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction, Eur J Prev Cardiol, 24 Shimokawa, 2015, Heart failure as a general pandemic in Asia, Eur J Heart Fail, 17, 884, 10.1002/ejhf.319 Piccolo, 2015, Stable coronary artery disease: revascularisation and invasive strategies, Lancet, 386, 702, 10.1016/S0140-6736(15)61220-X Reuter, 2012, Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects, Clin Pharmacokinet, 51, 553, 10.1007/BF03261931 Mock, 2012, Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy, Am J Health Syst Pharm, 69, 35, 10.2146/ajhp110049 Evans, 2003, Dialysis-related carnitine disorder and levocarnitine pharmacology, Am J Kidney Dis, 41, S13, 10.1016/S0272-6386(03)00113-6 Rick, 2017, 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, J Am Coll Cardiol, 70, 252, 10.1016/j.jacc.2017.03.011 Giannakoulas, 2016, Pulmonary arterial hypertension in congenital heart disease: Current perspectives and future challenges, Hellenic J Cardiol, 10.1016/j.hjc.2016.05.002 Otsuka, 2014, Has our understanding of calcification in human coronary atherosclerosis progressed?, Arterioscler Thromb Vasc Biol, 34, 724, 10.1161/ATVBAHA.113.302642 Valente, 2014, Diuretic response in acute heart failure: clinical characteristics and prognostic significance, Eur Heart J, 35, 1284, 10.1093/eurheartj/ehu065 Morrissey, 2011, Chronic heart failure: current evidence, challenges to therapy, and future directions, Am J Cardiovasc Drugs, 11, 153, 10.2165/11592090-000000000-00000 Schreiber, 2005, Levocarnitine and dialysis: a review, Nutr Clin Pract, 20, 218, 10.1177/0115426505020002218 Machado, 2009, Mitochondrial involvement in cardiac apoptosis during ischemia and reperfusion: can we close the box?, Cardiovasc Toxicol, 9, 211, 10.1007/s12012-009-9055-1 Pekala, 2011, L-carnitine--metabolic functions and meaning in humans life, Curr Drug Metabol, 12, 667, 10.2174/138920011796504536 Rizos, 2000, Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration, Am Heart J, 139, S120, 10.1067/mhj.2000.103917 Gürlek, 2000, The effects of L-carnitine treatment on left ventricular function and erythrocyte superoxide dismutase activity in patients with ischemic cardiomyopathy, Eur J Heart Fail, 2, 189, 10.1016/S1388-9842(00)00064-7